Duvelisib clinical trials
Also written IPI-145, Copiktra and INK-1197.
How each study uses duvelisib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the duvelisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Sept 2018 · COPIKTRA · NDA 211155 (FDA, Drugs@FDA)
- European Union
- 19 May 2021 · Copiktra · EMEA/H/C/005381 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2013 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 9 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 24
SecuraBio (23) · Washington University School of Medicine (3) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · AbbVie (2)
Often tested with
Tested in the same studies.
Nivolumab (3) · Azacitidine (3) · Cc-486 (2) · Tucidinostat (2) · Ruxolitinib (1) · Docetaxel (1) · Midazolam (1) · Rifampin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test duvelisib.
- May 2027Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2 · Alliance for Clinical Trials in Oncology
- Aug 2027A Study of Ruxolitinib and Duvelisib in People With LymphomaPhase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses duvelisib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT04803201Written as Duvelisib
- Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingPhase 2City of Hope Medical CenterNCT07293403Written as Duvelisib
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingPhase 1SecuraBioNCT07714187Written as Duvelisib
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT06810778Written as Duvelisib
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07001384Written as Duvelisib
- Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingPhase 2Liling ZhangNCT05976997Written as Duvelisib, Chidamide
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingPhase 3SecuraBioNCT06522737Written as Duvelisib
- Genotype-guided Treatment in Newly Diagnosed PTCLRecruitingPhase 1/2Ruijin HospitalNCT05675813Written as CHOP+duvelisib+5-Azacitidine
- Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04652960Written as Duvelisib
- A Study of Ruxolitinib and Duvelisib in People With LymphomaActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05010005Written as Duvelisib
- Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingPhase 2City of Hope Medical CenterNCT03961672Written as Duvelisib
- Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03534323Written as Duvelisib
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingPhase 1/2Dana-Farber Cancer InstituteNCT02158091Written as IPI-145
- Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCCompletedPhase 2Kartik Sehgal, MDNCT05057247Written as Duvelisib
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingPhase 1Washington University School of MedicineNCT05044039Written as Duvelisib
- Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasTerminatedPhase 2Washington University School of MedicineNCT04331119Written as Duvelisib
- Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaTerminatedPhase 1/2John KirkwoodNCT04688658Written as Duvelisib
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedPhase 2SecuraBioNCT03372057Written as Duvelisib
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedEarly Phase 1Emory UniversityNCT04890236Written as Duvelisib
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedPhase 2SecuraBioNCT04038359Written as Duvelisib
See all 50 studies that test duvelisib →
Given beside what is tested · 4 — duvelisib is usual care or a partner of the new treatment
- A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05508659Written as Duvelisib
- Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02783625Written as duvelisib
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05065866Written as Duvelisib
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedPhase 1/2SecuraBioNCT02391545Written as Duvelisib
Codes
What other systems call duvelisib · ClinicalTrials.gg INT006442
- MeSH (NLM) C586691duvelisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 610V23S0JIDUVELISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2058509One source FDA
- Wikidata Q27077129duvelisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99225DuvelisibOne source FDA
- DrugBank DB11952One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586691 | duvelisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 610V23S0JI | DUVELISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2058509 | — | One source FDA |
| Wikidata | Q27077129 | duvelisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99225 | Duvelisib | One source FDA |
| DrugBank | DB11952 | — | One source Wikidata |
Also registered as duvelisib monohydrate (UNII 4WD61MR063).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.